Objectives. To determine overexpression of p53

EGFR

c-erbB-2 and c-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic significance of these results

especially

coexisting overexpression of p53 and one of the member of type I growth factor receptor family.Methods. Overexpressions of the p53

EGFR

c-erbB-2 and c-erbB-3 protein were studied by im-munohistochemistry in paraffin-embedded tumor tissue from 28 patients with endometrioid carcinoma of the ovary.Results. 11 （39.3%）

13 （46. 4%）

and 14 （50. 0%） were stained positively with p53

c-erbB-2 and c-erbB-3 monoclonal antibodies. 13 （46- 4%） was stained positively with EGFR polyclonal antibody. There were no relationship between p53

EGFR

C-erbB-2

c-erbB-3 and histologic grade

lymph node metastasis. The percentage of tumors with over expression of p53

EGFR

C-erbB-2 and c-erbB-3 was higher in those with stage Ⅱ-Ⅲ tumors compared with those with stage Ⅰ

in patients with residual tumor after initial surgery compared with those without. A high survival rate was observed in patients without p53

EGFR

c-erbB-2 and c-erbB-3 overexpression respectively than those with. A highest survival rate was observed in patients with both p53 and one of EGFR

c-erbB-2 and c-erbB-3 negative compared with those both positive or either of both positive.Conclusion. Overexpression of p53

EGFR

c-erbB-2 and C-erbB-3 resulted in a poorer prognosis respectively. Overexpression of both p53 and one of the EGFR

c-erbB-2 and c-erbB-3 is a worse prognostic indicator in patients with endometrioid carcinoma of the ovary.